Medical marijuana is one of the biggest healthcare stories out there right now.
We know that cannabis is a godsend for cancer patients, who use it to control their nausea and increase their appetite following chemotherapy.
Researchers are proving every day that cannabis-based drugs are effective against extreme pain, epilepsy, multiple sclerosis, and other ailments.
Plus, because of marijuana’s effectiveness in the fight against pain, everyone from doctors to law enforcement leaders are looking to use weed to help end the ongoing – and devastating – opioid crisis.
All that means medical marijuana is also one of the best investment opportunities out there.
But when it comes to medical marijuana, there’s a big problem.
Marijuana is probably the least studied cash crop in the world.
Researchers working to discover and refine the medicinal properties of cannabis have been greatly hampered by the Drug Enforcement Agency’s (DEA) classification of the plant as a Schedule 1 drug. That means the federal government deems marijuana as having no accepted medical use, like meth or heroin.
That stance has cut down on the sort of well-funded research that’s needed to usher in the next round of cannabis-based wonder drugs.
But that doesn’t mean no research is happening. After all, GW Pharma and other biotech firms have produced a first round of weed-based drugs.
In fact, there’s a small but growing cottage industry of tiny startups focused on the genetic testing of cannabis to help those biotechs
Some marijuana analytics startups, like Steep Hill, are developing their own gene-sequencing systems – and that’s something very exciting I plan to tell you more about soon.
But most, including Medicinal Genomics, are using state-of-the-art gene-sequencing equipment from the company I want to tell you about today.
This dynamic industry leader is a pioneer in the genetic testing equipment field. And now it’s equipment is crucial for medical marijuana pioneers.
If you got in when I first recommended this stock just a few months ago, you’ve already made nearly 19%.
But thanks to the medical marijuana sector’s interest and several more catalysts I’ll tell you about below, it’s got a lot further to run.